Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 14/20 | 1.00 |
| ▸ | DRD3 | P35462 | 11/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 1.00 |
| ▸ | DRD5 | P21918 | 4/20 | 1.00 |
| ▸ | DRD4 | P21917 | 2/20 | 1.00 |
| ▸ | F3 | P13726 | 4/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.81 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | CASP1 | P29466 | 1/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.81 |
| ▸ | APAF1 | O14727 | 1/20 | 0.81 |
| ▸ | BCHE | P06276 | 1/20 | 0.81 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | TSHR | P16473 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16035972 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL14703846 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL29561422 | 1.00 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL2742469 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL21192511 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL231003 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL29999180 | 0.95 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| SCHEMBL13334113 | 0.94 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| Hydrochloric Acid SCHEMBL3321082 | 0.93 | DRD1 (0.98) | DRD1DRD2DRD3SIGMAR1DRD5 | |
| Stepholidine SCHEMBL10001965 | 0.93 | DRD1 (1.00) | DRD1DRD2DRD3SIGMAR1DRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106613129-A | Planting method for high-yield and high-quality white peony root | 枞阳县新农民农业种植有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) | 2016-06-30 | — | — | US | claimed |
| CN-103402499-A | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans | MALLINCKRODT LLC | 2013-11-20 | — | — | CN | claimed |
| EP-2654727-A1 | METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | Mallinckrodt LLC (US) | 2013-10-30 | — | — | EP | claimed |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MNK 2011 LLC (F/K/A MALLINCKRODT INC.) | 2013-10-17 | — | — | US | claimed |
| WO-2012087377-A1 | METHODS OF PRODUCING STABILIZED SOLID DOSAGE PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT LLC (US) | 2012-06-28 | — | — | WO | claimed |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-11-24 | — | — | US | claimed |
| WO-2011087765-A2 | METHODS OF PRODUCING STABILIZED SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANS | MALLINCKRODT INC. (US) | 2011-07-21 | — | — | WO | claimed |
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | Mallinkckrodt Inc. (US) | 2011-06-23 | — | — | US | claimed |
| WO-2011041470-A2 | SUSTAINED-RELEASE OPIATE AND OPIATE DERIVATIVE COMPOSITIONS | MALLINCKRODT INC. (US) | 2011-04-07 | — | — | WO | claimed |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | MALLINCKRODT INC. (US) | 2011-03-31 | — | — | US | claimed |
| EP-3517537-B1 | DEUTERATED DERIVATIVE OF L-TETRAHYDROPALMATINE AND MEDICAL USE THEREOF | TAIZHOU HUAYUAN MEDICINAL TECH CO LTD (CN) | 2023-09-13 | — | — | EP | disclosed |
| CN-106613129-A | Planting method for high-yield and high-quality white peony root | 枞阳县新农民农业种植有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.) | 2016-06-30 | — | — | US | disclosed |
| CN-103402499-B | Preparation comprises the method for the stable pharmaceutical composition as solid dosage form of morphinan | MALLINCKRODT LLC (US) | 2016-03-30 | — | — | CN | disclosed |
| WO-2004093876-A2 | COMPOSITION CONTAINING BERBERINE OR A DERIVATIVE THEREOF AND AN ANTIMICROBIAL AGENT OR AN ANTIBIOTIC AGENT, AND THEIR USE FOR TREATING ORAL PATHOGENS AND OTHER DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20020068097-A1 | Treatment for irritable bowel syndrome and related conditions | ANCILE PHARMACEUTICALS | 2002-06-06 | — | — | US | disclosed |
| WO-2001089546-A2 | TREATMENT FOR IRRITABLE BOWEL SYNDROME AND RELATED CONDITIONS | ANCILE PHARMACEUTICALS, INC. (US) | 2001-11-29 | — | — | WO | disclosed |
| CN-1280827-A | Sigma receptor action medicine containing alkaloid | CHENGDU INST BIOLOGY CAS (CN) | 2001-01-24 | — | — | CN | disclosed |
| US-4657861-A | S-tetrahydroprotoberberineoxidase, process for producing the same and use thereof | CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH (DE) | 1987-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110150989-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
| US-20110287095-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
| US-20110077222-A1 | Sustained-Release Opiate and Opiate Derivative Compositions | OPRL1, OPRK1, OPRM1 | DRD1 213/4885DRD2 85/4885DRD3 57/4885 |
| US-20130273153-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
| US-20160184232-A1 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans | LPXN, FSCN1, NCLN | DRD1 963/4885DRD2 1084/4885DRD3 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.